EUCTR2007-002736-28-FR进行中（未招募）1 期
A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old with metastatic breast cancer. - DOGMES
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- age > 70 years
- •- HER2-negative breast adenocarcinoma
- •- metastases cytologically or histoogically proven
- •- measurable or assessable disease
- •- life expectancy of at least 3 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- metastatic evolution < 6 months
- •- Previous malignancies in last 5 years
- •- patient having received more than 300 mg/m² of Doxorubicin ou more than 300 mg/m² of epirubicin in adjuvant
- •- congestive heart failure or LVEF < 50%
研究者
相似试验
招募中
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43
已完成
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD) + Carboplatin (CBDCA) as Treatment in Relapsed, Plutinum-sensitive Ovarian CancerOvarian cancerJPRN-UMIN000003944Osaka University Graduate School of Medicine Department of Obstetrics and Gynecology85
进行中（未招募）
不适用
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal TumorsGynecologic Sarcomas and Mixed Epithelial-Mesenchymal TumorsEUCTR2008-000245-55-DEGYN Research GmbH
进行中（未招募）
不适用
Dose finding study of Liposomal Doxorubicin Myocet in combination with Capecitabine Xeloda in the treatment of metastatic breast cancer patients - NDEUCTR2005-005885-36-ITAZIENDA USL DI FORLI30
进行中（未招募）
1 期
Phase II study evaluating the combination of liposomal doxorubicin pluscyclophosphamide with trastuzumab followed by docetaxel plustrastuzumab as therapy to be performed before surgery (neoadjuvantchemotherapy) for patients with breast cancer more than 2 cm in size and possible involvement of the lymph nodes adjacent and with the receptor HER2 positive.MedDRA version: 14.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864ocal advanced breast cancer resectable, neoadjuvant settingEUCTR2013-002684-25-ITS.I.C.O.G. ONLUS41